Post by GSK

Today, on Global Fatty Liver Day, we’re addressing some common misconceptions surrounding the liver diseases metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD), which each affect up to 5% of the global population. At GSK, we’re extending our deep expertise and understanding in immuno-inflammation to advance the science and support the needs of people living with these conditions. Our goal is to stop progression and improve fibrosis for the millions of people affected. Beyond scientific advancement, we’re committed to raising awareness and promoting earlier diagnosis, which are essential steps to improving outcomes. #FattyLiverDay

Video Content